07:16 AM EDT, 10/09/2024 (MT Newswires) -- Clearside Biomedical ( CLSD ) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes.

Among 60 participants in the trial who received CLS-AX, best corrected visual acuity and ocular anatomy were stable for up to six months compared to participants who received the drug aflibercept, the company said.

CLS-AX also showed a "well-tolerated" safety profile at week 36.

Clearside President and Chief Executive George Lasezkay said the results support advancing tests of the drug into phase 3 development.

Age-related macular degeneration causes a loss of central vision and is the most common cause of legal blindness in those over 55 years old.

Price: 1.8700, Change: +0.39, Percent Change: +26.35